INSERM Transfert SA (extinct)

INSERM Transfert SA (extinct)

INSERM Transfert SA (extinct)

Overview
Date Founded

2000

Headquarters

7, rue Watt,Paris, Ile-de-France 75013

Type of Company

Private

Industries

Private Equity & Venture Capital
Investment Services & Portfolio Management

Company Description

ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing.ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions.

Contact Data
Trying to get in touch with decision makers at INSERM Transfert SA? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Paths to INSERM Transfert SA
Potential Connections via
Relationship Science
You
INSERM Transfert SA
Investments
Details Hidden

ScreenCell SA offers clinically confirmed solutions for the isolation of rare cells in the blood and other fluids. It provides rare cell isolation solutions for medical and research applications. The company was founded on April 11, 2001 by Patrizia Paterlini-Brechot, Ian Jones and Christian Brechot and is headquartered in Sarcelles, France.

Details Hidden

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Details Hidden

Effimune SA engages in the research and development of drugs for transplantation and immune-mediated diseases. It covers the identification of novel therapeutic targets, the development of therapeutics, pilot manufacturing, set-up of animal models, pre-clinical and early clinical development. The company was founded by Maryvonne Hiance, Bernard Vanhove and Sophie Brouard in 2007 and is headquartered in Nantes, France.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by INSERM Transfert SA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of INSERM Transfert SA's profile does not indicate a business or promotional relationship of any kind between RelSci and INSERM Transfert SA.